High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

@article{Child2003HighdoseCW,
  title={High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.},
  author={J. Anthony Child and Gareth J. Morgan and Faith E Davies and Roger G. Owen and Sue E. Bell and Kim Hawkins and Julia Brown and Mark T. Drayson and Peter J. Selby},
  journal={The New England journal of medicine},
  year={2003},
  volume={348 19},
  pages={
          1875-83
        }
}
BACKGROUND High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma… Expand
Single Versus Tandem Autologous Hematopoietic Stem Cell Transplant in Multiple Myeloma
TLDR
The 5-year projected survival for the transplant group was 52 versus 12% for the standard therapy (SDT) group, and 22% of the high-dose therapy group achieved complete remissions (CR), showing an improvement in median event-free survival (EFS) and OS of approximately 12 months. Expand
Role of high-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma
TLDR
The role of autologous bone marrow transplantation in the management of multiple myeloma continues to be controversial, particularly since it is not a curative therapy, and further studies are necessary to further define the patient population most likely to benefit. Expand
High-Dose Therapy and Stem Cell Transplantation
Background: Multiple myeloma (MM) is the second most common hematologic malignancy, affecting approximately 14,000 new patients in the United State per year. The median overall survival is 5 years,Expand
Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma
Despite their sensitivity to alkylator-based chemotherapy, dose-intensive regimens with a source of hematopoietic support have only recently been exploited for the treatment of patients with multipleExpand
Stem cell transplantation for multiple myeloma.
  • C. Gasparetto
  • Medicine
  • Cancer control : journal of the Moffitt Cancer Center
  • 2004
TLDR
This strategy represents an advance in the treatment of MM, and evidence-based reviews indicate that there are a number of issues to consider regarding the induction therapy, the collection of stem cells, and the timing, type, and number of high-dose therapies to use in this type of treatment strategy. Expand
High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy
TLDR
Autologous stem cell transplant (SCT) improves survival in multiple myeloma (MM) and remains the standard of care for eligible patients and it is recommended that patients with primary refractory MM be offered early SCT. Expand
High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission
Summary:High-dose therapy (HDT) followed by autologous stem cell support is widely used as intensification treatment in patients with multiple myeloma (MM) responsive to the initial chemotherapy.Expand
High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years
TLDR
One or two cycles of high-dose chemotherapy with autologous hematopoietic stem cell transplantation have been shown to improve response rates and survival in myeloma, but there is no evidence so far that novel agents such as thalidomides, bortezomib and lenalidomide can replace high- dose chemotherapy and stem cell transplation. Expand
Stem cell transplantation in multiple myeloma
TLDR
High-dose treatment with autologous stem cell transplantation with ASCT has been shown to increase survival and time to progression in multiple myeloma compared with conventional chemotherapy, and the difference was most pronounced in patients with a high beta-2-microglobulin value at diagnosis. Expand
Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma
TLDR
Single agent dexamethasone appears to be an effective alternative to VAD for induction therapy prior to HDT in myeloma, given that it is the most active drug in these combinations. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 27 REFERENCES
A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma
TLDR
The response rate among the patients who received high-dose therapy was 81 percent, whereas it was 57 percent in the group treated with conventional chemotherapy (P<0.001). Expand
Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.
TLDR
Compared to ST, dose intensification with double AT markedly augments tumor cytoreduction, effecting not only higher CR rates but also significantly extending EFS and OS in previously untreated patients with MM. Expand
High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
TLDR
Myeloma patients who are able to receive HDM plus ABMT following conventional chemotherapy achieve a high proportion of CRs, which may be associated with prolonged survival. Expand
High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.
TLDR
HDR with PBSC transplantation obtained a median OS exceeding 5 years in young patients with symptomatic MM, whether performed early, as first-line therapy, or late, as rescue treatment, suggesting early HDT may be preferred because it is associated with a shorter period of chemotherapy. Expand
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.
TLDR
The results indicate that the introduction of high-dose therapy for newly diagnosed myeloma has resulted in prolonged survival for the total patient population aged less than 60 years. Expand
High-Dose Therapy and Stem Cell Transplantation.
  • Fields
  • Medicine
  • Cancer control : journal of the Moffitt Cancer Center
  • 1998
TLDR
This edition of Cancer Control focuses on several aspects of stem cell transplantation, including recent advances in management, as well as several controversies in the utilization of this therapy. Expand
Total therapy with tandem transplants for newly diagnosed multiple myeloma.
TLDR
Time-dependent covariate analysis suggested that timely application of a second transplant extended both EFS and OS significantly, independent of cytogenetics and beta-2-microglobulin. Expand
Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.
TLDR
The median survival time of patients with MM who are less than 65 years of age and who respond to initial chemotherapy is 5 years and the importance of ongoing randomized trials to determine the role of HDT in the treatment of younger myeloma patients is stressed. Expand
INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA
32 previously untreated patients with multiple myeloma received vincristine, doxorubicin ('Adriamycin'), and dexamethasone (VAD) as first-line therapy. The overall response rate was 84%, with 28% ofExpand
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
TLDR
Intensified chemotherapy followed by myeloablative therapy as first-line treatment for multiple myeloma resulted in a higher CR and a longer TTP when compared with intensified chemotherapy alone, however, it did not result in a better EFS and OS. Expand
...
1
2
3
...